Quantcast
Last updated on April 21, 2014 at 9:29 EDT
Researchers Discover Biomarker Leading To Cancer Drug

Researchers Discover Biomarker Leading To Cancer Drug Resistance

redOrbit staff & Wire Reports – Your Universe Online Researchers from the University of California, San Diego School of Medicine have located a biomarker that they believe could help explain why many of the medications used to treat...

Latest chemotherapy Stories

2014-04-19 23:00:54

Japanese research suggests a biomarker called osteopontin could help some mesothelioma patients avoid the trial-and-error approach to treatment. Raleigh, NC (PRWEB) April 19, 2014 Scientists say testing for the structural glycoprotein osteopontin in mesothelioma tissue samples could help streamline the process of selecting an effective treatment. Details on the new study have just been posted on the Cancer Monthly website and can be read by clicking here. Doctors in the Department of...

2014-04-18 12:30:44

Scientists have identified new pain relief targets that could be used to provide relief from chemotherapy-induced pain. BBSRC-funded researchers at King's College London made the discovery when researching how pain occurs in nerves in the periphery of the body. Dr Marzia Malcangio said: "We have been investigating and identifying mechanisms underlying pain generation and our findings could help chemotherapy patients who suffer pain related side effects." One potential side effect of...

2014-04-17 08:28:08

Company also announces designation of Orphan Drug Status by FDA for VTX-2337 in Ovarian Cancer SEATTLE, April 17, 2014 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc. today announced that enrollment has been completed in GOG-3003 (NCT01666444), a randomized, placebo-controlled Phase 2 trial of VTX-2337 in combination with Pegylated Liposomal Doxorubicin (PLD) in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer who have failed prior...

2014-04-15 08:29:16

Trial Will Evaluate Investigational Compound's Efficacy and Safety as an Addition to Standard Chemotherapy in Previously-Untreated Patients NORTH CHICAGO, Ill., April 15, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced the initiation of a global Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), in patients with previously untreated locally advanced or metastatic squamous non-small cell lung cancer (NSCLC). The trial...

2014-04-13 23:00:43

Transparency Market Research Report Added "Anti-Tumor Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019" to its database. Browse Full Report: http://www.transparencymarketresearch.com/anti-tumor-drugs-market.html. Albany, New York, USA (PRWEB) April 13, 2014 Tumor is also termed as neoplasm and it is caused by an abnormal proliferation of tissues. This abnormal proliferation can be due to genetic mutations. Tumors can be...

2014-04-10 23:24:17

Mexican researchers say an alternative to the standard mesothelioma chemotherapy regimen can not only improve survival and quality of life, but can also save money. Raleigh, NC (PRWEB) April 10, 2014 Scientists in the Thoracic Oncology Unit at Mexico’s National Cancer Institute say continuous infusions of low-dose Gemzar (gemcitabine) with cisplatin appear to be a safe and effective alternative to standard mesothelioma chemotherapy. Click here to read about the new study on the...

2014-04-10 12:26:46

Improved Overall Survival and Delayed Disease Progression are the Greatest Unmet Needs in this Population, According to Findings from Decision Resources Group BURLINGTON, Mass., April 10, 2014 /PRNewswire/ -- Decision Resources Group finds that interviewed oncologists are optimistic that emerging targeted therapies will offer efficacy advantages over current treatment options for metastatic gastric cancer. Physicians anticipate that Roche/Genentech/Chugai's Perjeta and...

2014-04-10 08:28:33

DUBLIN, April 10, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/qxfqmk/drug_delivery_in) has announced the addition of a new report "Drug Delivery in Cancer - Technologies, Markets and Companies" [http://www.researchandmarkets.com/research/qxfqmk/drug_delivery_in ] to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Drug delivery remains a challenge in management of cancer. Approximately 12.5...

2014-04-09 10:43:30

Among patients with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in survival without progression of the cancer, but not with overall survival, according to a study in the April 9 issue of JAMA. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred treatment option for...

2014-04-08 13:04:46

Trial identifies breast cancer patients likely to benefit from experimental drug In an innovative clinical trial led by UC San Francisco, the experimental drug neratinib along with standard chemotherapy was found to be a beneficial treatment for some women with newly diagnosed, high-risk breast cancer. Additionally, researchers learned that an algorithm used in the adaptive, randomized trial known as I-SPY 2 was highly effective at predicting the success of the treatment regimen in the...


Latest chemotherapy Reference Libraries

Intravenous Therapy
2013-04-30 13:16:16

Intravenous therapy, commonly known as IV therapy, is known as the administration of a liquid substance directly into a vein. It is also known as drip therapy, because most often the liquid is suspended above the IV site by an infusion pump, and runs through a drip chamber, which prevents air from entering the line. IVs are the preferred method of drug administration in hospital settings because they are the fastest known route of getting medication to the body. Intravenous therapy can also...

Antiviral Chemistry & Chemotherapy
2012-04-25 09:59:26

Antiviral Chemistry & Chemotherapy is a peer-reviewed academic journal published bi-monthly by International Medical Press in London since 1997. When founded in January 1990, it was published by Blackwell Science. The current editor-in-chief is Hugh J. Field of University of Cambridge, UK. The journal publishes primary papers and reviews on all aspects of the preclinical development of antiviral agents, including their chemical synthesis, biochemistry, pharmacology, mode of action and...

More Articles (2 articles) »